Tomasz M. Beer, MD | Authors

Midwest Benefit Pharmacy

Articles

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

June 15, 2015

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?

July 15, 2013

We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.